AU2022335932A1 - Novel dysfunctional p2x7 binders - Google Patents

Novel dysfunctional p2x7 binders Download PDF

Info

Publication number
AU2022335932A1
AU2022335932A1 AU2022335932A AU2022335932A AU2022335932A1 AU 2022335932 A1 AU2022335932 A1 AU 2022335932A1 AU 2022335932 A AU2022335932 A AU 2022335932A AU 2022335932 A AU2022335932 A AU 2022335932A AU 2022335932 A1 AU2022335932 A1 AU 2022335932A1
Authority
AU
Australia
Prior art keywords
seq
set forth
antigen binding
sequence set
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022335932A
Other languages
English (en)
Inventor
Julian Alexander Barden
Daniel Ulrich CHRIST
Patrick Schlegel
Peter Robert Schofield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosceptre Pty Ltd
Original Assignee
Biosceptre Aust Pty Ltd
Biosceptre Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902832A external-priority patent/AU2021902832A0/en
Application filed by Biosceptre Aust Pty Ltd, Biosceptre Pty Ltd filed Critical Biosceptre Aust Pty Ltd
Publication of AU2022335932A1 publication Critical patent/AU2022335932A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022335932A 2021-09-01 2022-09-01 Novel dysfunctional p2x7 binders Pending AU2022335932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902832A AU2021902832A0 (en) 2021-09-01 Methods and compositions for stimulating immune activity
AU2021902832 2021-09-01
PCT/AU2022/051066 WO2023028653A1 (en) 2021-09-01 2022-09-01 Novel dysfunctional p2x7 binders

Publications (1)

Publication Number Publication Date
AU2022335932A1 true AU2022335932A1 (en) 2023-11-30

Family

ID=85410590

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022335932A Pending AU2022335932A1 (en) 2021-09-01 2022-09-01 Novel dysfunctional p2x7 binders
AU2022341030A Pending AU2022341030A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022341030A Pending AU2022341030A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Country Status (8)

Country Link
US (2) US20240376193A1 (https=)
EP (2) EP4395814A4 (https=)
JP (2) JP2024532482A (https=)
CN (2) CN117813109A (https=)
AU (2) AU2022335932A1 (https=)
CA (2) CA3223086A1 (https=)
MX (2) MX2023015028A (https=)
WO (2) WO2023028657A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4400516A1 (en) * 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CN119792512A (zh) * 2020-10-14 2025-04-11 维里迪安治疗公司 用于治疗甲状腺眼病的组合物和方法
TW202320850A (zh) 2021-08-10 2023-06-01 美商維里迪恩醫療股份有限公司 用於治療甲狀腺眼病之組合物、劑量及方法
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター （オースト） プロプライエタリー・リミテッド 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells
AU2024306505A1 (en) * 2023-06-30 2025-10-16 Biosceptre (Aust) Pty Ltd Molecules and methods for activating car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904911T3 (es) * 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
JP5992831B2 (ja) * 2009-12-24 2016-09-14 バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
EP3347474B1 (en) * 2015-09-11 2020-11-04 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威（英国）有限公司 细胞毒性颗粒
EP3797164A4 (en) * 2018-05-21 2022-03-02 Biosceptre (Aust) Pty Ltd CHIMERIC ANTIGEN RECEPTORS WITH MODIFIED LINKER DOMAINS AND THEIR USES
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
KR20210148228A (ko) * 2019-03-27 2021-12-07 내셔날 리서치 카운실 오브 캐나다 항-EGFRvIII 항체 및 그의 항원-결합 단편
JP2024510739A (ja) * 2021-03-11 2024-03-11 バイオセプター （オースト） プロプライエタリー・リミテッド 新規な細胞治療システム

Also Published As

Publication number Publication date
EP4395813A1 (en) 2024-07-10
WO2023028657A1 (en) 2023-03-09
AU2022341030A1 (en) 2023-11-30
EP4395814A1 (en) 2024-07-10
CA3223079A1 (en) 2023-03-09
CA3223086A1 (en) 2023-03-09
CN117881421A (zh) 2024-04-12
EP4395813A4 (en) 2025-07-09
US20240368282A1 (en) 2024-11-07
US20240376193A1 (en) 2024-11-14
EP4395814A4 (en) 2025-09-03
WO2023028653A1 (en) 2023-03-09
CN117813109A (zh) 2024-04-02
MX2023015469A (es) 2024-01-19
JP2024532489A (ja) 2024-09-05
JP2024532482A (ja) 2024-09-05
MX2023015028A (es) 2024-02-16

Similar Documents

Publication Publication Date Title
AU2022335932A1 (en) Novel dysfunctional p2x7 binders
EP2953971B1 (en) Il-11r binding proteins and uses thereof
US20190352390A1 (en) Antibodies to il-37
EP2718326B1 (en) Antibodies against g-csfr and uses thereof
US20260098096A1 (en) Anti-ccr8 antibodies
US20220332804A1 (en) Complement C2 Binding Proteins and Uses Thereof
WO2019169448A1 (en) Multi-specific antibodies
US20240109971A1 (en) Ccr6 antibodies
WO2025171447A1 (en) Antibodies for binding ccr6
WO2025260123A1 (en) Anti-c2 antibodies and uses thereof
HK40098034A (en) Il-11r binding proteins and uses thereof
HK40015686B (zh) Il-11r结合蛋白及其应用
HK1217502B (en) Il-11r binding proteins and uses thereof
NZ617725B2 (en) Antibodies against g-csfr and uses thereof
HK1196384B (en) Antibodies against g-csfr and uses thereof
HK1196384A (en) Antibodies against g-csfr and uses thereof